3 active not recruiting, 3 terminated, 1 completed, 1 recruiting. 8 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 3, Terminated 3, Completed 1, Recruiting 1 |
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1 |
Follow NeoImmuneTech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia Recombinant human interleukin (IL) 7-hyFc - Idiopathic CD4 Lymphopenia | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2024-11-06 | 2026-10-19 |
| Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Biospecimen Collection, Efineptakin alfa, Pembrolizumab - High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Active not recruiting | Mayo Clinic | 53 | 2023-01-24 | 2026-10-05 |
| Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer GX-188E, GX-I7, Pembrolizumab, GX-188E, Pembrolizumab, GX-188E, GX-I7 - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Yonsei University | 56 | 2022-03-01 | 2026-02-09 |
| NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC efineptakin alfa, Atezolizumab - Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer | Phase 2 | Terminated | NeoImmuneTech | 33 | 2021-11-15 | 2026-06-11 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors NT-I7, pembrolizumab (KEYTRUDA®) - Any Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | NeoImmuneTech | 215 | 2020-06-10 | 2026-03-09 |
| High-Risk Skin Cancers With Atezolizumab Plus NT-I7 NT-I7, atezolizumab - Melanoma, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | NeoImmuneTech | 31 | 2019-12-26 | 2025-10-22 |
| rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide rhIL-7-hyFc, Placebo, Temozolomide - Glioma | Phase 1 / Phase 2 | Active not recruiting | Washington University School of Medicine | 42 | 2019-01-04 | 2025-11-25 |
| Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Docetaxel, Carboplatin, FDG-PET/MR - Triple Negative Breast Neoplasms | Phase 2 | Terminated | Washington University School of Medicine | 148 | 2014-07-07 | 2022-11-07 |
Carcinoma, Non-Small-Cell Lung (2) · Triple Negative Breast Neoplasms (2) · Carcinoma (1) · Carcinoma, Merkel Cell (1) · Glioblastoma (1) · Glioma (1) · Gliosarcoma (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Opportunistic Infections (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Small Cell Lung Carcinoma (1)
efineptakin alfa (6) · pembrolizumab (3) · atezolizumab (2) · Biopsy (1) · Carboplatin (1) · Docetaxel (1) · Radiotherapy (1) · Specimen Handling (1) · Temozolomide (1) · gosha-jinki-gan (1)
United States (7) · South Korea (1)
Andrea Lisco, M.D. (1) · Brian Gastman, MD (1) · Donghoon Choi, PhD (1) · Foluso Ademuyiwa, M.D., MPH (1) · Hye Ryun Kim (1) · Jian L. Campian, MD, PhD (1) · Martin Cheever, MD (1) · Milan Chheda, M.D. (1) · NgocDiep Le, MD, PhD (1)
R01CA288862 (1), U24CA209837 (1)